Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q4 2022 · 10-K
Revenue$1.92M$1.92M+64.0% vs Q4 2021 Net Income-$6.35M-$6.35MN/M vs Q4 2021 EPS Diluted-$0.03-$0.03no prior Q4 2021 on file Gross Profitderived$1,813,000+88.1% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Income-$6,639,000N/M Operating Cash Flowderived-$8,303,000N/M Free Cash Flowderived-$8,287,000N/M Margins · derivedGross margin94.7%+12.1 pt vs Q4 2021
Operating margin-346.7%+2071.0 pt vs Q4 2021
Net margin-331.8%+2150.4 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 9, 2023 · 68 d after period end